Funding for this research was provided by:
Received: 2 January 2019
Accepted: 29 July 2019
First Online: 13 August 2019
Ethics approval and consent to participate
: Patient data were de-identified by an independent statistical expert following the Health Insurance Portability and Accountability Act of 1996 procedures and managed according to customer data use agreements. In the United States, Institutional Review Board/Independent Ethical Committee approval and written informed consent by patients are not required for such retrospective analyses using de-identified secondary data.
: Not applicable.
: RM reports grants from Acceleron Pharma, Bayer, Daiichi Sankyo, and Exelixis; personal fees* from Advanced Medical, Grand Rounds, InfiniteMD, Bayer, and Exelixis; and employment from Flatiron Health.SO reports personal fees* from Bayer and Eisai.FX reports employment from Bayer.MF reports employment from Bayer.FP reports grants from Esaote; and personal fees* from AstraZeneca, Bayer, Bracco Diagnostics, Bristol-Myers Squibb, and Eisai.*Personal fees as defined by ICMJE as “Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliation (e.g. advisory boards) etc.”